By Michael Dabaie

AC Immune SA said a Phase 2 trial of semorinemab didn't meet the co-primary efficacy endpoint or two secondary endpoints for early Alzheimer's disease.

Swiss-based clinical-stage biopharmaceutical company AC Immune said its partner, Roche Group's Genentech, informed the company of the top-line results of the trial, which showed semorinemab didn't meet its co-primary goal of reducing the decline on Clinical Dementia Rating-Sum of Boxes compared to a placebo.

The secondary endpoints of Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 and Alzheimer's Disease Cooperative Study Group -- Activities of Daily Living Inventory also weren't met, AC Immune said.

The company said additional data analyses are ongoing and Genentech plans to present the results from the trial at an upcoming medical congress. The second Phase 2 study of semorinemab in patients with moderate Alzheimer's disease remains ongoing, the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

September 23, 2020 07:44 ET (11:44 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
AC Immune (NASDAQ:ACIU)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas AC Immune.
AC Immune (NASDAQ:ACIU)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas AC Immune.